Profusa
NASDAQ: PFSASan Francisco, US · California corporation · 4 known investors
Profusa develops injectable hydrogel biosensors and AI-driven health platforms that enable real-time measurement of body chemistry from within tissue. The company's Lumee platform addresses oxygen monitoring for vascular surgery patients and continuous glucose monitoring for diabetes and prediabetes patients.
Founders & leadership
BF
Bill FawcettCo-founder
BH
Ben HealyCEO
NW
Natalie WisniewskiExecutive Officer, Director
QK
Qianye Karen LiuDirector
BH
Ben HwangExecutive Officer, Director
TG
Thomas GutshallDirector
FC
Fred Craven
DK
Dr. Katharine Rebrin
AT
Aude Taibi
SP
Sean Patterson
Investors · 4
Reported raises · per SEC filings
Form D private placements▶$45.1MraisedSep 2018 · 46 investors · Other Health CareRule 506(b)
▶$45.1MraisedSep 2018 · 46 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- NG Siu WaiDirector
- Bill McMillanExecutive Officer
- Natalie WisniewskiExecutive Officer, Director
- Joan BraddiDirector
- Ben HwangExecutive Officer, Director
- William FristDirector
- Thomas GutshallDirector
- Qianye Karen LiuDirector
- Offering amount
- $50M
- Amount sold
- $45.1M
- First sale
- May 2018
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$11.3MraisedJul 2015 · 32 investors · Other Health CareRule 506(b)
▶$11.3MraisedJul 2015 · 32 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Natalie WisniewskiExecutive Officer, Director
- Qianye Karen LiuDirector
- Ben HwangExecutive Officer, Director
- Thomas GutshallDirector
- Offering amount
- $17M
- Amount sold
- $11.3M
- First sale
- Jun 2015
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Profusa CEO urges shareholders to vote on Nasdaq listing proposals By Investing.cominvesting.com · 2026
- Profusa (PFSA) registers 179.3M resale shares, up to $100M ELOC fundingstocktitan.net · 2026
- Profusa raises 2026 revenue forecast on European purchase orders By Investing.cominvesting.com · 2026
- Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidanceglobenewswire.com · 2026